Description
Introduction:
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favor. It can be used as both injection-type and oral-type drug.
Intended Use:
The KRIBIOLISA Anti-Semaglutide (Ozempic) ELISA kit is used for estimation of antibodies to Semaglutide in human serum and plasma.
Principle:
The Anti-Semaglutide ELISA is a sandwich immunoassay for the determination of antibodies to Semaglutide. Semaglutide is coated on 96 well plates. Anti-GLP1 or antibodies to Semaglutide present in sample will bind to the plate. Plates are washed and Goat Anti-Mouse + Goat Anti-Human HRP conjugate is added which binds to bound antibodies. Washing is performed to remove any unbound material. TMB substrate is added and the enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is directly proportional to the amount of Anti Semaglutide antibody present in standards or samples.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!